These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

528 related articles for article (PubMed ID: 17536877)

  • 21. Risk of diabetes with fibrates and statins: a pharmacoepidemiological study in VigiBase
    Montastruc F; Benevent J; Rousseau V; Durrieu G; Sommet A; Montastruc JL
    Fundam Clin Pharmacol; 2019 Feb; 33(1):108-112. PubMed ID: 30098074
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Risk factors and drug interactions predisposing to statin-induced myopathy: implications for risk assessment, prevention and treatment.
    Chatzizisis YS; Koskinas KC; Misirli G; Vaklavas C; Hatzitolios A; Giannoglou GD
    Drug Saf; 2010 Mar; 33(3):171-87. PubMed ID: 20158283
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Relationship between statins and the risk of amyotrophic lateral sclerosis: A PRISMA-compliant meta-analysis.
    Chang MC; Kwak SG; Park JS; Park D
    Medicine (Baltimore); 2021 Jul; 100(30):e26751. PubMed ID: 34397718
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Diplopia, blepharoptosis, and ophthalmoplegia and 3-hydroxy-3-methyl-glutaryl-CoA reductase inhibitor use.
    Fraunfelder FW; Richards AB
    Ophthalmology; 2008 Dec; 115(12):2282-5. PubMed ID: 18930555
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Statins and risk of amyotrophic lateral sclerosis: a systematic review and meta-analysis.
    Nabizadeh F; Balabandian M; Sharafi AM; Ghaderi A; Rostami MR; Naser Moghadasi A
    Acta Neurol Belg; 2022 Aug; 122(4):979-986. PubMed ID: 34322852
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Influence of statins treatment on survival in patients with amyotrophic lateral sclerosis.
    Drory VE; Bronipolsky T; Artamonov I; Nefussy B
    J Neurol Sci; 2008 Oct; 273(1-2):81-3. PubMed ID: 18678378
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A potential event-competition bias in safety signal detection: results from a spontaneous reporting research database in France.
    Salvo F; Leborgne F; Thiessard F; Moore N; Bégaud B; Pariente A
    Drug Saf; 2013 Jul; 36(7):565-72. PubMed ID: 23673817
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Relationship of statins and other cholesterol-lowering medications and risk of amyotrophic lateral sclerosis in the US elderly.
    Freedman DM; Kuncl RW; Cahoon EK; Rivera DR; Pfeiffer RM
    Amyotroph Lateral Scler Frontotemporal Degener; 2018 Nov; 19(7-8):538-546. PubMed ID: 31112080
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Statin-associated myopathy.
    Thompson PD; Clarkson P; Karas RH
    JAMA; 2003 Apr; 289(13):1681-90. PubMed ID: 12672737
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Statins and erectile dysfunction: results of a case/non-case study using the French Pharmacovigilance System Database.
    Do C; Huyghe E; Lapeyre-Mestre M; Montastruc JL; Bagheri H
    Drug Saf; 2009; 32(7):591-7. PubMed ID: 19530745
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Disease-related adverse events following non-live vaccines: investigation of a newly described reporting bias through the analysis of the WHO Global ICSR Database, VigiBase.
    Roberto G; Zanoni G
    Vaccine; 2014 May; 32(26):3328-35. PubMed ID: 24291198
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Rhabdomyolysis reported for children and adolescents treated with antipsychotic medicines: a case series analysis.
    Star K; Iessa N; Almandil NB; Wilton L; Curran S; Edwards IR; Wong IC
    J Child Adolesc Psychopharmacol; 2012 Dec; 22(6):440-51. PubMed ID: 23234587
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Statins and immune-mediated necrotizing myopathy: Variability in the risk.
    Trenque T; Hadjoudj J; Trenque A; Tralongo F; Martin S; Azzouz B
    Therapie; 2024; 79(3):365-370. PubMed ID: 37625939
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Statin use and risk of amyotrophic lateral sclerosis and other motor neuron disorders.
    Sørensen HT; Riis AH; Lash TL; Pedersen L
    Circ Cardiovasc Qual Outcomes; 2010 Jul; 3(4):413-7. PubMed ID: 20530788
    [TBL] [Abstract][Full Text] [Related]  

  • 35. HMG-CoA-reductase inhibitors and neuropathy: reports to the Netherlands Pharmacovigilance Centre.
    de Langen JJ; van Puijenbroek EP
    Neth J Med; 2006 Oct; 64(9):334-8. PubMed ID: 17057271
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Rhabdomyolysis and HMG-CoA reductase inhibitors.
    Omar MA; Wilson JP; Cox TS
    Ann Pharmacother; 2001 Sep; 35(9):1096-107. PubMed ID: 11573861
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Statins--the pattern of adverse effects with empahsis on mental reactions. Data from a national and an international database].
    Buajordet I; Madsen S; Olsen H
    Tidsskr Nor Laegeforen; 1997 Sep; 117(22):3210-3. PubMed ID: 9411859
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Impact of safety alerts on measures of disproportionality in spontaneous reporting databases: the notoriety bias.
    Pariente A; Gregoire F; Fourrier-Reglat A; Haramburu F; Moore N
    Drug Saf; 2007; 30(10):891-8. PubMed ID: 17867726
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Physician response to patient reports of adverse drug effects: implications for patient-targeted adverse effect surveillance.
    Golomb BA; McGraw JJ; Evans MA; Dimsdale JE
    Drug Saf; 2007; 30(8):669-75. PubMed ID: 17696579
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Drug-induced liver injury in Switzerland: an analysis of drug-related hepatic disorders in the WHO pharmacovigilance database VigiBase from 2010 to 2020.
    Ortland I; Mirjalili M; Kullak-Ublick GA; Peymani P
    Swiss Med Wkly; 2021 May; 151():w20503. PubMed ID: 34000058
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 27.